Xenetic interim CEO granted 100,000 XBIO shares

PARSLOW JAMES F reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

PARSLOW JAMES F reported acquisition or exercise transactions in this Form 4 filing.

Xenetic Biosciences, Inc. reported that Interim CEO and CFO James F. Parslow received a grant of 100,000 shares of Common Stock as a restricted stock grant. The award was made at a stated price of $0.00 per share, indicating compensation rather than a market purchase.

According to the vesting terms, 7,000 shares vest on the grant date, and one-third of the remaining 93,000 shares will vest on each of the first, second, and third anniversaries of April 21, 2026. Following this grant, Parslow directly holds 100,000 shares of Xenetic Biosciences common stock.

Insider Trade Summary 10b5-1

Grant/Award: 100,000 shares

Grant/Award 1 txn

Insider PARSLOW JAMES F

Role Interim CEO and CFO

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	100,000	$0.00	$0.00

Holdings After Transaction: Common Stock — 100,000 shares (Direct)

Footnotes (1)

1. F1. This represents a restricted stock grant ("RSG"). The shares represented by the RSG will vest and become exercisable as follows: 7,000 shares shall vest on the date of grant and one-third of the remaining (93,000) shares shall vest on each of the first, second and third anniversaries of April 21, 2026.

Key Figures

Restricted stock grant: 100,000 shares Grant price: $0.00 per share Immediate vesting portion: 7,000 shares +2 more

5 metrics

Restricted stock grant 100,000 shares Common Stock award to Interim CEO and CFO James F. Parslow

Grant price $0.00 per share Stated transaction price for the 100,000-share grant

Immediate vesting portion 7,000 shares Shares vesting on the grant date under the RSG

Remaining vesting pool 93,000 shares Balance that vests over three anniversaries of April 21, 2026

Post-transaction holdings 100,000 shares Total Common Stock directly owned after the grant

Key Terms

restricted stock grant, RSG, vest

3 terms

restricted stock grant financial

"This represents a restricted stock grant ("RSG")."

A restricted stock grant is an award of company shares given to an employee or executive that cannot be sold or transferred until certain conditions are met, such as staying with the company for a set time or hitting performance goals. For investors, it signals how the company ties pay to future performance and can affect the number of shares outstanding and management’s incentives—think of it as a wrapped gift you only keep once you meet the requirements.

RSG financial

"This represents a restricted stock grant ("RSG")."

vest financial

"The shares represented by the RSG will vest and become exercisable as follows:"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Xenetic Biosciences (XBIO) report for James F. Parslow?

Xenetic Biosciences reported that Interim CEO and CFO James F. Parslow received a grant of 100,000 shares of Common Stock. The filing classifies this as a restricted stock grant used for compensation rather than as an open-market purchase or sale.

How many Xenetic Biosciences (XBIO) shares were granted in the latest Form 4?

The Form 4 shows a grant of 100,000 shares of Xenetic Biosciences Common Stock to Interim CEO and CFO James F. Parslow. All 100,000 shares are reported as directly owned following the transaction, reflecting his current reported stock position from this filing.

What is the vesting schedule for James F. Parslow’s Xenetic Biosciences restricted stock grant?

The restricted stock grant vests over time. 7,000 shares vest on the grant date, while one-third of the remaining 93,000 shares will vest on each of the first, second, and third anniversaries of April 21, 2026, subject to the stated terms.

Was cash paid for the 100,000 Xenetic Biosciences (XBIO) shares granted to James F. Parslow?

The Form 4 lists a transaction price of $0.00 per share for the 100,000-share grant. This indicates the award is compensation in the form of restricted stock, not a cash-funded, open-market share purchase by the executive.

How many Xenetic Biosciences (XBIO) shares does James F. Parslow hold after this transaction?

After the restricted stock grant, the filing shows James F. Parslow directly owning 100,000 shares of Xenetic Biosciences Common Stock. This total reflects his reported holdings immediately following the grant recorded in the Form 4.

What role does James F. Parslow hold at Xenetic Biosciences (XBIO) in this Form 4?

In this filing, James F. Parslow is identified as the Interim CEO and CFO of Xenetic Biosciences. The 100,000-share restricted stock grant represents equity-based compensation linked to his executive responsibilities at the company.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/23/2026 - 05:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

PARSLOW JAMES F

(Last) (First) (Middle)

945 CONCORD STREET

(Street)

FRAMINGHAM MASSACHUSETTS 01701

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Xenetic Biosciences, Inc. [ XBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Interim CEO and CFO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/21/2026		A(1)		100,000	A	$0	100,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This represents a restricted stock grant ("RSG"). The shares represented by the RSG will vest and become exercisable as follows: 7,000 shares shall vest on the date of grant and one-third of the remaining (93,000) shares shall vest on each of the first, second and third anniversaries of April 21, 2026.

	/s/ James Parslow	04/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)